A story this week about an FDA Form 483 filing for an Ajinomoto site in San Diego was reported in error. While the site did receive FDA observations in early 2023, the inspection has since closed. The story also placed the Form 483 in the wrong context. In light of these errors, we have taken the necessary steps to retract the article, and Fierce Pharma apologizes for the error.